These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34171438)

  • 41. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Establish a predictive modeling under antiviral therapy for hepatitis B e antigen seroconversion in chronic hepatitis B].
    Liu GW; Tang KC; Li Q; Lu W
    Zhonghua Gan Zang Bing Za Zhi; 2018 Sep; 26(9):641-645. PubMed ID: 30481858
    [No Abstract]   [Full Text] [Related]  

  • 43. [Evidence based antiviral therapy for chronic hepatitis B].
    Okanoue T; Minami M
    Nihon Shokakibyo Gakkai Zasshi; 2005 Oct; 102(10):1253-8. PubMed ID: 16262155
    [No Abstract]   [Full Text] [Related]  

  • 44. Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
    Walsh R; Hammond R; Yuen L; Deerain J; O'Donnell T; Leary T; Cloherty G; Gaggar A; Kitrinos K; Subramanian M; Wong D; Locarnini S
    Liver Int; 2019 Nov; 39(11):2066-2076. PubMed ID: 31379058
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
    J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Focus.
    Shouval D
    J Hepatol; 2013 Dec; 59(6):1151-2. PubMed ID: 24021425
    [No Abstract]   [Full Text] [Related]  

  • 47. Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B.
    Chen H; Ding X; Liao G; Xia M; Ren Z; Fan R; Peng J
    J Viral Hepat; 2021 Aug; 28(8):1121-1129. PubMed ID: 33899998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients.
    Na JH; Kim JH; Choe WH; Kwon SY; Yoo BC
    Korean J Gastroenterol; 2021 Jun; 77(6):285-293. PubMed ID: 34158448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.
    Tseng TC; Kao JH
    J Gastroenterol; 2013 Jan; 48(1):13-21. PubMed ID: 23090000
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disputing issues in the paradigm change to finite antiviral therapy in HBeAg-negative patients.
    Jeng WJ; Chien RN; Liaw YF
    J Hepatol; 2021 Dec; 75(6):1498-1499. PubMed ID: 34214616
    [No Abstract]   [Full Text] [Related]  

  • 51. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status.
    Liu F; Liu ZR; Li T; Liu Y; Zhang M; Xue Y; Zhang LX; Ye Q; Fan XP; Wang L
    J Dig Dis; 2018 Sep; 19(9):561-571. PubMed ID: 30098114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
    Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
    [No Abstract]   [Full Text] [Related]  

  • 55. Deep sequencing identifies hepatitis B virus core protein signatures in chronic hepatitis B patients.
    van der Ree MH; Jansen L; Welkers MRA; Reesink HW; Feenstra KA; Kootstra NA
    Antiviral Res; 2018 Oct; 158():213-225. PubMed ID: 30121196
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
    Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL
    Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
    Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL
    Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Seroreversion and Acute Decompensation in Chronic Hepatitis B after Discontinuation of Oral Nucleotide Analog in the Patients Achieving HBsAg Loss].
    Cho HJ; Shin SK; Kwon OS; Kim JH; Kim YS
    Korean J Gastroenterol; 2020 Nov; 76(5):256-260. PubMed ID: 33234774
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.